Michelle Davis
Family · Riverton, UTNPI 1568075604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,931, more than ten times the $25 reported in 2021. Among family clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$782
- GSK$493
- Genentech USA, Inc.$460
- Amgen$415
- Regeneron Healthcare Solutions, Inc.$363
- plus $918 from 15 others
What the payments were for
- Food & beverage$4,39799%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,008 |
| Sanofi | 32 | $782 |
| GSK | 15 | $493 |
| Genentech USA, Inc. | 9 | $460 |
| Amgen | 11 | $415 |
| Regeneron Healthcare Solutions, Inc. | 10 | $363 |
| Incyte Corporation | 7 | $194 |
| Novartis | 8 | $151 |
| Organon | 3 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| Blueprint Medicines Corporation | 1 | $75 |
| Biocryst US Sales Co., LLC | 3 | $63 |
| Kaleo, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| Cycle Pharmaceuticals Inc | 2 | $27 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,439 in reported general payments places this provider in the 90th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 18 | $372 |
| Azelastine Hcl | 16 | $318 |
| Montelukast Sodium | 11 | $235 |
Paid to pharmacies, not to this prescriber.
Other family in Riverton
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.